Literature DB >> 26926624

Ampicillin in Combination with Ceftaroline, Cefepime, or Ceftriaxone Demonstrates Equivalent Activities in a High-Inoculum Enterococcus faecalis Infection Model.

Megan K Luther1, Louis B Rice2, Kerry L LaPlante3.   

Abstract

Ampicillin-ceftriaxone combination therapy has become a predominant treatment for serious Enterococcus faecalis infections, such as endocarditis. Unfortunately, ceftriaxone use is associated with future vancomycin-resistant enterococcus colonization. We evaluated E. faecalis in an in vitro pharmacodynamic model against simulated human concentration-time profiles of ampicillin plus ceftaroline, cefepime, ceftriaxone, or gentamicin. Ampicillin-cefepime and ampicillin-ceftaroline demonstrated activities similar to those of ampicillin-ceftriaxone against E. faecalis.
Copyright © 2016, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 26926624      PMCID： PMC4862448          DOI： 10.1128/AAC.03126-15

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  36 in total

1.  Association between vancomycin-resistant Enterococci bacteremia and ceftriaxone usage.

Authors:  James A McKinnell; Danielle F Kunz; Eric Chamot; Mukesh Patel; Rhett M Shirley; Stephen A Moser; John W Baddley; Peter G Pappas; Loren G Miller
Journal:  Infect Control Hosp Epidemiol       Date:  2012-05-14       Impact factor: 3.254

2.  The combination of ampicillin plus ceftaroline is synergistic against Enterococcus faecalis.

Authors:  Brian J Werth; April N Abbott
Journal:  J Antimicrob Chemother       Date:  2015-05-07       Impact factor: 5.790

3.  A dose-ranging study of gentamicin pharmacokinetics: implications for extended interval aminoglycoside therapy.

Authors:  D R McNamara; A N Nafziger; A M Menhinick; J S Bertino
Journal:  J Clin Pharmacol       Date:  2001-04       Impact factor: 3.126

4.  Evaluation of ceftaroline activity versus daptomycin (DAP) against DAP-nonsusceptible methicillin-resistant Staphylococcus aureus strains in an in vitro pharmacokinetic/pharmacodynamic model.

Authors:  Molly Steed; Celine Vidaillac; Michael J Rybak
Journal:  Antimicrob Agents Chemother       Date:  2011-05-16       Impact factor: 5.191

5.  Infective endocarditis: diagnosis, antimicrobial therapy, and management of complications: a statement for healthcare professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, and the Councils on Clinical Cardiology, Stroke, and Cardiovascular Surgery and Anesthesia, American Heart Association: endorsed by the Infectious Diseases Society of America.

Authors:  Larry M Baddour; Walter R Wilson; Arnold S Bayer; Vance G Fowler; Ann F Bolger; Matthew E Levison; Patricia Ferrieri; Michael A Gerber; Lloyd Y Tani; Michael H Gewitz; David C Tong; James M Steckelberg; Robert S Baltimore; Stanford T Shulman; Jane C Burns; Donald A Falace; Jane W Newburger; Thomas J Pallasch; Masato Takahashi; Kathryn A Taubert
Journal:  Circulation       Date:  2005-06-14       Impact factor: 29.690

6.  Modification of Streptococcus faecalis sex pheromones after acquisition of plasmid DNA.

Authors:  Y Ike; R A Craig; B A White; Y Yagi; D B Clewell
Journal:  Proc Natl Acad Sci U S A       Date:  1983-09       Impact factor: 11.205

Review 7.  Infective Endocarditis in Adults: Diagnosis, Antimicrobial Therapy, and Management of Complications: A Scientific Statement for Healthcare Professionals From the American Heart Association.

Authors:  Larry M Baddour; Walter R Wilson; Arnold S Bayer; Vance G Fowler; Imad M Tleyjeh; Michael J Rybak; Bruno Barsic; Peter B Lockhart; Michael H Gewitz; Matthew E Levison; Ann F Bolger; James M Steckelberg; Robert S Baltimore; Anne M Fink; Patrick O'Gara; Kathryn A Taubert
Journal:  Circulation       Date:  2015-09-15       Impact factor: 29.690

8.  Brief communication: treatment of Enterococcus faecalis endocarditis with ampicillin plus ceftriaxone.

Authors:  Joan Gavaldà; Oscar Len; José M Miró; Patricia Muñoz; Miguel Montejo; Aristides Alarcón; Julián de la Torre-Cisneros; Carmen Peña; Xavier Martínez-Lacasa; Cristina Sarria; Germán Bou; José M Aguado; Enrique Navas; Joan Romeu; Francesc Marco; Carmen Torres; Pilar Tornos; Ana Planes; Vicenç Falcó; Benito Almirante; Albert Pahissa
Journal:  Ann Intern Med       Date:  2007-04-17       Impact factor: 25.391

9.  In vitro activity of ceftaroline against 623 diverse strains of anaerobic bacteria.

Authors:  D M Citron; K L Tyrrell; C V Merriam; E J C Goldstein
Journal:  Antimicrob Agents Chemother       Date:  2010-01-25       Impact factor: 5.191

10.  Vancomycin dosing in patients undergoing maintenance hemodialysis.

Authors:  Aleksandra Rymarz; Dorota Brodowska-Kania; Małgorzata Gomółka; Elżbieta Józefczak-Bergier; Małgorzata Dzierżanowska; Stanisław Niemczyk
Journal:  Int Urol Nephrol       Date:  2014-04-03       Impact factor: 2.370
View more
  5 in total

1.  Pharmacodynamics of Ceftaroline plus Ampicillin against Enterococcus faecalis in an In Vitro Pharmacokinetic/Pharmacodynamic Model of Simulated Endocardial Vegetations.

Authors:  Brian J Werth; Laura M Shireman
Journal:  Antimicrob Agents Chemother       Date:  2017-03-24       Impact factor: 5.191

2.  Meropenem plus Ceftaroline Is Active against Enterococcus faecalis in an In Vitro Pharmacodynamic Model Using Humanized Dosing Simulations.

Authors:  Jaclyn A Cusumano; Kathryn E Daffinee; Emily C Piehl; Mónica García-Solache; Charlene Desbonnet; Louis B Rice; Kerry L LaPlante
Journal:  Antimicrob Agents Chemother       Date:  2022-09-26       Impact factor: 5.938

Review 3.  A Review of Combination Antimicrobial Therapy for Enterococcus faecalis Bloodstream Infections and Infective Endocarditis.

Authors:  Maya Beganovic; Megan K Luther; Louis B Rice; Cesar A Arias; Michael J Rybak; Kerry L LaPlante
Journal:  Clin Infect Dis       Date:  2018-07-02       Impact factor: 9.079

Review 4.  Infectious disease: how to manage Gram-positive and Gram-negative pathogen conundrums with dual beta-lactam therapy.

Authors:  Alireza FakhriRavari; Brenda Simiyu; Taylor Morrisette; Yewande Dayo; Jacinda C Abdul-Mutakabbir
Journal:  Drugs Context       Date:  2022-01-20

5.  Ampicillin-Ceftriaxone vs Ampicillin-Gentamicin for Definitive Therapy of Enterococcus faecalis Infective Endocarditis: A Propensity Score-Matched, Retrospective Cohort Analysis.

Authors:  Niyati H Shah; Kathleen A Shutt; Yohei Doi
Journal:  Open Forum Infect Dis       Date:  2021-03-06       Impact factor: 3.835
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.